UNIVERSAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH (UJPSR)
Volume 9 Issue 2 Year 2023 Page No. 32 – 51
Estd. 1990

HETEROCYCLIC COMPOUNDS: AS ANTIDIABETIC DRUGS

Manjeela Subba[1*], ShubhamNain[2],Gurvinder Singh[2]

Article History
Received : 12th April 2023
Revised : 9th June 2023
Accepted : 1st August 2023
Published : 31st December 2023

Keywords
Diabetes mellitus, Anti-diabetes, treatment, heterocyclic moieties, type 1 diabetes mellitus, type 2 diabetes mellitus

Abstract
Diabetes can have long-term consequences by causing damage to essential organs, blood vessels, and nerves. Diabetes prevalence continues to climb internationally, with poorer nations bearing the brunt of the burden. Diabetes mellitus is a condition characterised by insufficient glucose management in the blood. Type 1 diabetes, type 2 diabetes, neonatal diabetes, maturity-onset diabetes of the young, gestational diabetes and steroid-induced diabetes are all subtypes. Since sickness is essentially because of the shortfall of insulin, insulin organization through day-to-day infusions, or an insulin siphon, is the backbone of therapy. Traditional oral drug therapy is described in the paper. In type 2 diabetes mellitus, diet and exercise might be satisfactory medicines, particularly at first. Different treatments might insulin awareness or increment insulin emission by the pancreatic islets. The particular classes for drugs incorporate thiazolidinediones, biguanides, sulfonylureas, dipeptidyl peptidase-IV inhibitors, alpha-glucosidase inhibitors, glucagon like-peptide-1 agonist, sodium-glucose carrier 2 inhibitors and meglitinides. And peer review of many heterocyclic moieties used as synthesis of anti-diabetic compound is described. Heterocyclic moieties like oxazole, thiazole, pyrrole, piperazine and many more are explained for generation of antidiabetic compounds having a significant therapeutic effect their structures are also provided and if structure activity relationship is explained for the heterocyclic compounds mentioned and what functional group changes can be possible for significant antidiabetic effect. As several of the pharmacological candidates mentioned show potential as an effective anti-diabetic chemotherapy, this study provides a platform for future medication design and development targeting diabetes treatment (i.e. optimization by structural derivatization).

INTRODUCTION

The term "diabetes mellitus" refers to a metabolic condition with a variety of etiologies characterised by persistent hyperglycemia and worsening fat, carbohydrate, and protein digestion caused by flaws in insulin emission, insulin activity, or both. Long-term injury, brokenness, and disappointment of many organs are all effects of diabetes mellitus[1].

Types of diabetes mellitus:

Type 1 diabetes mellitus often appears in childhood stage and immaturity, and require lifetime insulin infusions for survival of an individual.

Type 2 diabetes mellitus often appears in maturity and is associated with obesity, a lack of physical labour, and poor eating habits. This is among a large population kind of diabetes mellitus, and therapy may consist of lifestyle modifications and oral drug therapy or even insulin infusion [2].

Categories of diabetes mellitus

Diabetes mellitus is classified into several types, including gestational diabetes (a hyperglycemic syndrome that develops during pregnancy) and "other" more unusual causes (hereditary disorders, obtained cycles, for example, pancreatitis, illnesses like cystic fibrosis, openness to specific medications, infections, and obscure causes)[3].

FACT

A dramatic increase was recognised in year 2014 where a 422 million people suffering from diabetes mellitus with a gap difference of only in a decade. Widespread of diabetes-related health issues are among in lower health index countries and those lower annual income, who actually cannot afford initial diagnosis. Diabetes is a major cause of vision loss, renal failure, coronary artery disease, and appendage removal.

From year 2000 and 2016, 5% increase in diabetes-related premature death. Diabetes mellitus was the tenth major cause for death in 2019, with approximately 1.5 million deaths [4].

Sign and Symptoms

Signs and symptoms for diabetes mellitus are mentioned below[5]:

[1]*Himalayan Pharmacy Institute,Majitar,Sikkim(737136)*
[2]*Lovely Professional University,Phagwara,Punjab(144402)*
For correspondence: subbamanjeela@gmail.com

- Weight loss
- Urge for thirst
- Ketones bodies presence in the urine
- Irritability
- Urge for urination
- Extreme hunger
- Fatigue
- Frequent infections
- Blurred vision

Drug therapy for diabetes mellitus

Since sickness is essentially because of the shortfall of insulin, insulin organization through day to day infusions, or an insulin siphon, is the backbone of therapy[6]. In type 2 diabetes mellitus, diet and exercise might be satisfactory medicines, particularly at first. Different treatments might insulin awareness or increment insulin emission by the pancreatic islets[7]. The particular classes for drugs incorporate thiazolidinediones, biguanides, sulfonylureas, dipeptidyl peptidase-IV inhibitors, alpha-glucosidase inhibitors, glucagon like-peptide-1 agonist, sodium-glucose carrier 2 inhibitors and meglitinides [8] as referenced in table 1.

Table 1: Drug therapy for management of Type 2 Diabetes Mellitus

• Subgroup	Generic name (Brand)	Structure
Biguanides	Metformin (1)	 (1)
Thiazolidinediones	Rosiglitazone (2) Pioglitazone (3)	 (2)  (3)
Sulfonylureas	Chlorpropamide (4) Glimepiride (5) Glipizide (6) Glyburide (7) Tolazamide (8)	 (4)  (5)

		 (6)  (7)  (8)
Glinides	Nateglinide (9) Repaglinide (10)	 (9)  (10)
inhibits alpha glucosidase	Acarbose (11) Miglitol (12)	 (11)

		 (12)
glucagon-like peptide-1 receptor agonist	Exenatide (13)	 (13)
DPP-4 inhibitors	Sitagliptin (14), Saxagliptin (15), Linagliptin (16), Alogliptin (17)	 (14)  (15)  (16)  (17)

Pramlintide	Pramlintide (18)	 (18) Golden line indicates disulfide bond
Rapid-release bromocriptine	Bromocriptine (19)	 (19)
SGLT-2 inhibitors	Canagliflozin (20) Dapagliflozin (21) Empagliflozin (22)	 (20)  (21)  (22)

OXADIAZOLE



1,3,4-oxadiazole (9)

Orchestrated a progression of 1,3,4-oxadiazoles as referenced in table 2, 10(a-j) (a):H^+, (b):Cl^-, (c):Br^-, (d): F^-, (e):$CH3^-$, (f):I^-, (g):NO2, (h):OCH3, (i):SCH3, (j):CF3, (k):N(CH3)2 involving 2-mercapto benzimidazole was evaluated for *in-vivo* antidiabetic movement utilizing test for glucose tolerance[9]. A portion of the mixture was evaluated for fantastic antidiabetic movement and furthermore pharmacophore got from dynamic particles proposed that presence of - OH bunch was a typical element in every single dynamic compound. Blended a progression of furoxan-based nitric oxide-delivering chrysin subsidiaries. Pharmacological tests showed that all chrysin subordinates displayed in vitro inhibitory exercises against aldose reductase and progressed glycation final result development[10]. Some chrysin subsidiaries were additionally found to build the glucose utilization of Hepatic G2 cells. Besides, the mixtures delivered a low measure of Nitric Oxide within the sight of L-cysteine. This cross breed furoxan-based Nitric Oxide benefactor chrysin subsidiaries offer a common prodrug plan idea for the improvement of remedial or preventive specialists for vascular intricacies because of diabetes[11].

Table 2: Oxadiazole compound showing maximum antidiabetic activity

 (10a-j)	 (11)
R= Halogenated Aryl or Heterocyclic Ring (a): H^+, (b, c, d): Halogens, (e): CH_3, (f): I, (g):NO_2, (h): OCH_3, (i): SCH_3, (j): CF_3, (k): $N(CH_3)_2$	

OXAZOLE



1,3-oxazole (12)

An oxazole subordinate with IUPAC (R)-3-amino-1-(2-cyclopropyl-6,7-dihydrooxazolo[4,5-c]pyridin-5(4H)-yl)-4-(2,5-difluorophenyl)butan-1-one(13) was developed to have extensive Dipeptidyl peptidase -IV restraint[12]. Oxazole subsidiaries was incorporated and furthermore, resulted Protein tyrosine-1B inhibitory movement. Tyrosine phosphatase-1B has been viewed as significant for the utilization and management of diabetes and corpulence. The mixtures, 13 and 14 displayed the most encouraging movement[13]. Planned and blended 1,3-dioxane corrosive subsidiaries and joined oxazole and assessed them for *in vitro* and *in vivo* potential of compound and profile for lipids lowering adequacy in creature models utilizing tesaglitazar and rosiglitazone as standard mixtures[14]. Compound 15 was viewed as the most dynamic. Planned and incorporated thiophene subbed oxazole

composed of α-alkoxy-phenylpropanoic corrosive subsidiaries as profoundly intense Peroxisome double agonists[15]. Peroxisome proliferator-actuated receptors assume a vital part in metabolic condition whose significant appearances are hyperglycaemia, dyslipidaemia and weight. Compound 16 was viewed as the most solid double agonist and showed the glucose decrease significantly[16]. The constructions of the most dynamic antidiabetic substance synthesized (13-17) are displayed in table 3.

Table 3: Oxazole Compound Showing Maximum Antidiabetic Activity

Compound	Structure
13	
14	

15	
16	
17	

PYRROLLE (18)



(18)

Current restorative methodologies which remember insulin obstruction with the assistance of Rosiglitazone and other of this subclass, expanding secretion of insulin by thoroughly use of sulfonylureas and biguanides are connected to each other with its undesirable after effects like hypoglycaemia, gastrointestinal problems and beta-cell apoptosis[17]. A few investigations evaluated that Dipeptidyl peptidase IV inhibitors address another pharmacological subclass for the maintenance[18]. Dipeptidyl peptidase IV is an omnipresent yet explicit proteolysis compound serine protease that divides terminal dipeptides from polypeptides by recurrent terminal position of L-proline or of L-alanine[19]. It remains alive in two structures for example a protein bound to plasma and a solvent in plasma. The incomparable reason for *in-vivo* activity of dipeptidyl peptidase IV inhibitors against glucagon like peptidase-1. An incretin which changes blood glucose levels[20]. The L-cells and invigorates delivery and biosynthesis of insulin, represses and builds the gastric acid purging time which brings about decreasing the hunger. Be that as it may, dynamic Increatins can be quickly corrupted by Dipeptidyl peptidase IV[21]. Planned and blended a progression of freshly developed β-aminopyrrole-2-carbonitrile group subsidiaries and evaluated them as antidiabetic movement with standard form of medication. Compound 19 was uncovered as a viable and particular Dipeptidyl peptidase IV inhibitors lowers blood sugar profile. [22, 23]. It showed great Dipeptidyl peptidase IV inhibition action when contrasted, with vildagliptin which was utilized as certain control[24, 25]. Planned and integrated a progression of formally developed subbed a-amino pyrrole-2-carbonitrile group containing subsidiaries in light of Structure activity of pyrrole-2-carbonitrile inhibitors[26, 27]. Compound 19,20 showed magnificent inhibitory movement against Dipeptidyl peptidase IV when contrasted with sitagliptin which was utilized as a standard medication[27] (Table 4)

Table 4: Pyrrole Compound showing maximum antidiabetic activity

19.		❖ Amide moiety will bind to active site of Dipeptidyl peptidase-4 Strong electron withdrawing group will increases potency of compound i.e. I, OCH_3 ❖ Cyano group enhances compound interaction with DPP4 ❖ Bicyclic ring present is responsible for hydrophobic interaction with amino acids.
20.		❖ Nitrile site enhances activity of adduct formation with catalytic site of Ser630. ❖ Thiazole ring should remain unsubstituted. ❖ Amino acids of Dipeptidyl peptidase-4 receptor will interact more in presence F atom

THIAZOLE (21)



(21)

Thiazole cross variants have been shown to have anti-diabetic properties. Diabetes mellitus is a metabolic disorder characterised by abnormalities in insulin output, insulin mobility, or both. [28]. Absence of insulin were causing persistent hyperglycaemia with unsettling influences of digestion. Tissue or vascular harm prompts genuine diabetic confusions, for example retinopathy, nephropathy, cardiovascular intricacies and neuropathological conditions in advanced sickness[29]. Along these lines, diabetes incorporates different heterogeneous illnesses. Diabetes mellitus can be disconnected into various types, but type-1 and type-2 are the two essential sorts. As a matter of first importance, drugs are used to save human life and alleviate the sickness. The point is to prevent long stretch diabetic complexities and assurance a more expanded life by getting rid of various bet factors[30]. Benzofuran-thiazole hybrids were mixed. also, pursued for glucose-cutting down sway in rodents. Considering the agonistic activity, compound 22 and 23 decided for oral glucose opposition test. Rodents were randomized into 4 get-togethers, bundle I for control, pack II for dynamic compound Fasiglifam, bundle III for compound 24 and social affair IV for compound 25[31]. All social events dosed with %30 glucose plan after 30 min. Blood tests were assembled in various times and assessed by blood glucose test strips. Gigantic decrease of blood glucose levels found in compound 26 treated pack[32]. That glucose-cutting down sway was generally something almost identical with Fasiglifam. Coordinated isatin-thiazole hybrids of 27a to 27p and pursued for in-vitro α-glucosidase inhibitory activity. Those blends showed extreme to coordinate α-glucosidase inhibitory development developing more than acarbose. Compound 28 (R1: 5-Me), (R2: 2-F-Benzyl), (R3: OH) showed the most essential inhibitory development[33]. Thiazole crossbreeds containing piperazine and piperidine investigated for their malonyl-Coenzyme A decarboxylase inhibitory effects alongside their antidiabetic works out. The joined combinations were used for the limitation of human activity. Taking into account the construction action relationship focuses on escalates 12, 13 were picked for a 14-day progressing feasibility studies in huge mice[34]. These blends were shown to diminish food confirmation and body weight, while compound 25 showed no basic effect. Heightens 11 and 12 made 186% and 70% developments in malonyl Coenzyme An at piece of 100 damaging palmometer keratoderma treatment[35]. The type-2 anti-glucokinase activity of new pyrane and thiazole cross variations was investigated. The Glucokinase activity of the combined blends was isolated using well-padded mice. The majority of the blends demonstrated a preference for control over the no-subbed compound 26a.[36, 37]. Furthermore, in both normal and Type-2 diabetes animal models, a single oral administration of 26b effectively lowered mice blood glucose levels. As -glucosidase inhibitors, triazine and thiazole crossbreeds were synthesised. The development of -glucosidase inhibitory activity in mixed mixtures was varied. Compound 27i (R1: Br, R2: OMe) demonstrated the most significant development.[38]. The looked at consequences of tried compounds, the discoveries showed that electron-pulling out bunch (F or Br) at R_1 expanded movement[39, 40]. Arranged a movement of triazole, thiazole, and oxadiazole with thiazole half and parts and examined for hypoglycemic and hypolipidemic practises in rats against plasma glucose and fatty substance levels. In vivo, all of the thiazole hybrids were seen to have lower plasma glucose and fatty oil levels.[41-43]. After oral administration of various portions of the synthesised chemical, diabetic male rat competitors began. It has been discovered that the union of para-methoxy and pyridyl bundles into the development updates insulin action, as it enhances 28a-c.[44, 45]. The delayed effects of therapy revealed that a wire with a thioethyloxy linkage and two carbon spacers interacting with heterocyclic moieties exhibited exceptional activity. Half and portions of 1,3,5-triazine and thiazoles (31a-j) were blended and considered for their anti-dipeptidyl peptidase-4 deterrent properties rather than their anti-dipeptidyl peptidase-4 deterrent properties.[46, 47] The aftereffect information addresses that each of the mixtures resulted huge inhibitory movement against Dipeptidyl peptidase-4[48, 49]. Its restraint, while compound 30 (R_1: H) and 29 (R_1: 4-F) showed the most powerful hindrance[50].

Table 5: Thiazole Compound showing maximum antidiabetic activity

22	
23	
24	
25	
26	

27	
28a	
28b	
29a-q	

30	
31a-j	
Compound 32 R = CF3	

To research glucose-bringing down impact in vivo, various portions of compound 32 were assessed in mice, a hereditary imperfection model with metabolic issues, for example, diabetes-related corpulent and insulin resistance[51, 52]. As displayed the double agonist showed hypoglycemic impact in a portion subordinate way, with changes in plasma glucose.

IMIDAZOLE (33)



(33)

Various compounds involving imidazoline as core moiety have been accounted for to prompt insulin

discharge from disengaged pancreas and all the more significantly to further develop glucose resistance in the two rodents and two non-rodents[53, 54]. The imidazoline receptor site is capable of presenting pancreatic β-cells, which has been named the abnormal imidazoline or I3 recently distinguished I1 and I2 locales found in different tissues[55]. Considering above, concentrated on the I3 receptor opposing action of 2-(2-ethyl-2,3-dihydrobenzo[b]furan-2-yl)-1H-imidazole(34) on plasma level *in-vivo*, and proposed that these medications might act at destinations other than I3 receptor to decrease blood glucose enacted protein kinases is a significant flagging effector that couples cell digestion and capacity[56]. The impacts of activated protein kinases initiation on pancreatic beta-cell work stay unsettled. Considering above, utilized 5-aminoimidazolecarboxamideriboside (35) is an activator of it[57], characterize the flagging instruments connecting the actuation of it with insulin discharge. From the review they presume that animated insulin discharge by both K^+ ATPase channel-subordinate and - free pathway Imidazoline subsidiaries have been accounted for to show antihyperglycemic movement in vivo[58, 59]. Considering above, Planned and blended novel imidazoline subordinates and evaluated them for their strong enemy of hyperglycemic action in type-2 diabetes mellitus in rodent model[60, 61]. Orchestrated mixtures of, 2-(a-cyclohexyl-benzyl)-4,5-dihydro-1H-imidazole(36,37) displayed intense enemy of hyperglycemic property having pKi upsides of 7.23 and 7.38 against imidazoline inclining toward restricting destinations I1 and I2, individually[62, 63].

Table 6: Imidazole Compound showing maximum antidiabetic activity



BENZIMIDAZOLE (38)



(38)

Viewed that as 3-(2,4-dichlorobenzyl)-2methyl-N-(pentylsulphonyl)-3H-benzimidazole-5-carboxamide(39), further develop insulin opposition in mammalian creature model through actuation of peroxisome proliferator activation receptor-δ intervened transcriptional movement subsequently [64]compound 39 is considered as an original remedial possibility for treatment of type 2 diabetic patients[65]. Completed an enhancement investigation of action which lead to the distinguishing proof, 40 as displayed in conspire 41, which it is a strong, metabolically steady and midway infiltrate as incomplete agonist[66]. Presented different replacement of carbon at 2nd position of the focal benzimidazole (42) nucleus of telmisartan for Peroxisome proliferator activation receptor-δ initiation[67, 68].

Table 7: Benzimidazole Compound showing maximum antidiabetic activity



(39)



(40)



R = (i) -C_4H_9, (ii) iso-C_4H_9 (iii) tert-C_4H_9, (iv) -C_6H_5, (41)



(42)

Benzimidazole as Glycogen Activator

Glucokinase is a catalyst which work with glucose-6-phosphate and happens overwhelmingly in the liver and pancreatic β-cells[69, 70]. Glucokinase assumes a significant part in starch digestion. In this way, actuation causes an expansion in hepatocytic cells glucose take-up and use[71]. It is important to specify that its action is connected with increment insulin emission in beta cells[72, 73]. Appropriately, activators of glucokinases can go about as hypoglycaemic specialists through the accompanying instruments: I) An expansion of hepatic glucose reuptake and ii) invigorating insulin discharge from pancreatic β-cells[74]. In view of this reasoning, different little particles were orchestrated as

[1]*Himalayan Pharmacy Institute,Majitar,Sikkim(737136)*
[2]*Lovely Professional University,Phagwara,Punjab(144402)*
For correspondence: subbamanjeela@gmail.com

Glucokinases Activators. Compound 2-(pyridine-2-yl)-1H-benzimidazole (43) glucokinase activators were explored. Thoroughly primary alteration of benzimidazole [75]headed to intensify 43 which was distinguished from a high throughput screening[76, 77].



(43)

Substance 44 viewed as a powerful glucokinase activator. The compound likewise has an intense oral glucose bringing down viability in rodent Oral glucose tolerance test model[78, 79].



(44)

Glycosidases Receptor Target of Benzimidazole.

Glycosidases are gathering of chemicals answerable for the hydrolytic invasion of glyosidic securities in complex starches[80, 81]. The possible focuses on advancement of antidiabetic drugs. 2nd position substituted benzimidazole subordinates were ready by and assessed action on rodent digestive α-glucosidase hindrance[82, 83]. Substance number 45 showed nearly 95% hindrance of yeast and rodent digestive α-glucosidase chemical while [84, 85]compound 46 showed approximately 75±1% restraint. Compound number 30 was viewed as the most powerful inhibitor for digestive α-glucosidase generating an IC50 worth of 99 μM[86]. Intensifies 45th, 46th showed huge antihyperglycemic movement in starch-instigated postprandial hyperglycemia in rodents[87-89].



(45)



(46)

PIPERAZINE (47)



(47)

The generated Bicyclic piperazine subsidiary of general equation below are useful in human [90, 91]and veterinary medications for preventing illnesses such as obesity, diabetes, metabolic issues, cardiovascular sickness, or upheaval associated with G-protein coupled receptor activity in patients[92]. In human embryonic kidney-293 cells, these newly created particles were tested for their ability to activate G-protein receptor119 and generate increases in cyclic-Adenosine [93]Monophosphate levels, with an increasing effectiveness. Similarly, G-protein receptor 88 has strong articulation in the central nervous system, with quantitative articulation in peripheral organs such

as the liver, and so its flagging may contribute to metabolic cycle guidance[90].

Table 8: Piperazine Compound showing maximum antidiabetic activity

	Ar= substituted aryl and heteroaryl etc W= O and NR1, absent; R_1= H, C_1-C_6 alkyl R_2 & R_3= H, or-CH2-CH2; X=-CH2-CH2 , CHR4, absent Y= CHR5, absent; R4 & R5= H, or -CH2-CH2 Z= -CH2-CH2 , CHR8; R6, R9& R10= H R7& R8= H, C1 -C6alkyl, CH2-CH2 etc R11= C1 -C6alkoxycarbonly, C1 -C6alkylthiocarbonyl, C4 -C13cycloalkylalkyl, heteroaryl etc;R15= H and CN (48)

COUMARIN

New glucose production in the liver and other organs such as the kidney may also contribute to a higher plasma glucose level [94]. In diabetic animals, coumarin reduced the hepatic gluconeogenic proteins glucose-6-phosphatase and fructose-1,6-bisphosphatase[95]. Umbelliferone reduced blood glucose and HbA1c levels, as well as the activity of the enzyme's glucose-6-phosphatase and fructose-1,6-bisphosphatase. Furthermore, it increased plasma insulin, liver glycogen, glucokinase, and glucose-6-phosphate dehydrogenase in diabetic animals[97, 98]. Coumarin-3-carboxylic destructive auxiliaries inhibited lactate uptake by a few of malignant cell types [99]. Hepatic difference in lactate is one of the known instruments for gluconeogenesis [100].

CONCLUSION

These compounds have potential pharmacological actions and are deserving candidates for diabetes control. Many of these possible pharmacological agonists and antagonists are not yet in clinical trials, but they highlight the urgency of further derivatization in order to give an option for controlling diabetes more efficiently and effectively in the future. Furthermore, these agents with promising activity and well-defined mechanisms of action might be regarded as helpful prototypes in the design and development of innovative and more potent synthetic compound-based modulators. Hence various heterocyclic moieties-based approach for antidiabetic effects have been remained successful in past year in development of oral medication and also can be successful approach for synthesis of many novel compounds in future.

REFERENCES

1. Organisation, W.H. *Diabetes*. 2022 [cited 2022 17/01]; Available from: https://www.who.int/health-topics/diabetes#tab=tab_1.
2. Healthline. *Type of Diabetes*. 2022 [cited 2022 17/01]; Available from: https://www.healthline.com/health/diabetes/types-of-diabetes.
3. Preventation, C.f.D.C.a. *Gestational Diabetes*. 2022 August 10, 2021 [cited 2022 17/01]; Available from: https://www.cdc.gov/diabetes/basics/gestational.html#:~:text=Gestational%20diabetes%20is%20a%20type,pregnancy%20and%20a%20healthy%20baby.
4. Rochester, U.o.R.M.C. *Facts about Diabetes*. 2022 [cited 2022 17/01]; Available from: https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=85&contentid=P00335.

5. Clinic, M. *Diabetes*. 2022 [cited 2022 17/01]; Available from: https://www.mayoclinic.org/diseases-conditions/ diabetes/symptoms-causes/syc-20371444.
6. Knowler, W.C., et al., *Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.* 2002.
7. Clinic, C. *Diabates Mellitus Treatment*. 2022 [cited 2022 21/01]; Available from: https://www.clevelandclinicmeded. com/medicalpubs/diseasemanagement/endocrinology/ diabetes-mellitus-treatment/.
8. Marín-Peñalver, J.J., et al., *Update on the treatment of type 2 diabetes mellitus.* World journal of diabetes, 2016. 7(17): p. 354.
9. Shingalapur, R.V., et al., *Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies.* European journal of medicinal chemistry, 2010. 45(5): p. 1753-1759.
10. Zou, X.-Q., et al., *Furoxan nitric oxide donor coupled chrysin derivatives: synthesis and vasculoprotection.* Bioorganic & medicinal chemistry letters, 2011. 21(4): p. 1222-1226.
11. GILANI, S.J., et al., P*rogress in the pharmacological potential of oxadiazoles: a review*. International Bulletin of Drug Research. 2(1): p. 132-146.
12. Ashton, W.T., et al., *Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole.* Bioorganic & medicinal chemistry letters, 2005. 15(9): p. 2253-2258.
13. Kakkar, S. and B. Narasimhan, *A comprehensive review on biological activities of oxazole derivatives.* BMC chemistry, 2019. 13(1): p. 1-24.
14. Kumar, A., et al., *Novel 2-aryl-naphtho [1, 2-d] oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities.* European journal of medicinal chemistry, 2009. 44(1): p. 109-116.
15. Pingali, H., et al., *Design and synthesis of novel oxazole containing 1, 3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists.* Bioorganic & medicinal chemistry, 2008. 16(15): p. 7117-7127.
16. Raval, P., et al., *Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.* Bioorganic & medicinal chemistry letters, 2011. 21(10): p. 3103-3109.
17. Isomaa, B., *A major health hazard: the metabolic syndrome.* Life sciences, 2003. 73(19): p. 2395-2411.
18. Ross, S.A., E.A. Gulve, and M. Wang, *Chemistry and biochemistry of type 2 diabetes.* Chemical reviews, 2004. 104(3): p. 1255-1282.
19. group, U., *UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients.* Metabolism, 1990. 39(9): p. 905-912.
20. Witters, L.A., *The blooming of the French lilac.* The Journal of clinical investigation, 2001. 108(8): p. 1105-1107.
21. Yaron, A., F. Naider, and S. Scharpe, *Proline-dependent structural and biological properties of peptides and proteins.* Critical reviews in biochemistry and molecular biology, 1993. 28(1): p. 31-81.
22. Gorrell, M., V. Gysbers, and G. McCaughan, *CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.* Scandinavian journal of immunology, 2001. 54(3): p. 249-264.
23. Gautier, J., et al., *Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.* Diabetes & metabolism, 2005. 31(3): p. 233-242.
24. Mojsov, S., G.C. Weir, and J.F. Habener, *Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.* The Journal of clinical investigation, 1987. 79(2): p. 616-619.
25. Nauck, M.A., et al., *Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.* The Journal of Clinical Endocrinology & Metabolism, 2002. 87(3): p. 1239-1246.
26. Wettergren, A., et al., *Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man.* Digestive diseases and sciences, 1993. 38(4): p. 665-673.
27. Ji, X., et al., *Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.* European journal of medicinal chemistry, 2014. 75: p. 111-122.
28. Salim, B., *Diabetes mellitus and its treatment.* 2005.
29. Serné, E.H., et al., *Belangrijke wijziging van behandelrichtlijn 'Diabetes mellitus type 2'.* Nederlands Tijdschrift voor Geneeskunde, 2021. 165.
30. Shah, B.M., P. Modi, and P. Trivedi, *Recent medicinal chemistry approach for the development of dipeptidyl peptidase IV inhibitors.* Current Medicinal Chemistry, 2021. 28(18): p. 3595-3621.
31. Xie, Z., et al., *Synthesis, biological evaluation, and molecular docking studies of novel isatin-thiazole*

derivatives as α-glucosidase inhibitors. Molecules, 2017. 22(4): p. 659.
32. Tang, H., et al., *Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.* Bioorganic & medicinal chemistry letters, 2010. 20(20): p. 6088-6092.
33. Li, F., et al., *Design, synthesis, and pharmacological evaluation of N-(4-mono and 4, 5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators.* Bioorganic & medicinal chemistry, 2010. 18(11): p. 3875-3884.
34. Wang, G., et al., *Synthesis, biological evaluation, and docking studies of novel 5, 6-diaryl-1, 2, 4-triazine thiazole derivatives as a new class of α-glucosidase inhibitors.* Bioorganic Chemistry, 2018. 78: p. 195-200.
35. Iqbal, A.M., et al., *Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring.* European journal of medicinal chemistry, 2012. 53: p. 308-315.
36. Gao, H.-D., et al., *Sulfonamide-1, 3, 5-triazine–thiazoles: discovery of a novel class of antidiabetic agents via inhibition of DPP-4.* RSC advances, 2016. 6(86): p. 83438-83447.
37. Gümüş, M., M. Yakan, and İ. Koca, *Recent advances of thiazole hybrids in biological applications.* Future Medicinal Chemistry, 2019. 11(16): p. 1979-1998.
38. Ibrahim, S.A. and H.F. Rizk, *Synthesis and biological evaluation of thiazole derivatives*, in *Azoles-Synthesis, Properties, Applications and Perspectives*. 2020, IntechOpen.
39. Li, Z., et al., *Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.* Bioorganic Chemistry, 2018. 77: p. 429-435.
40. Li, Z., et al., *Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.* European Journal of Medicinal Chemistry, 2019. 164: p. 352-365.
41. Li, Z., et al., *ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis.* Pharmacological Research, 2020. 159: p. 105035.
42. Li, Z., et al., *Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.* Bioorganic Chemistry, 2019. 92: p. 103254.
43. Falomir-Lockhart, L.J., et al., *Fatty acid signaling mechanisms in neural cells: fatty acid receptors.* Frontiers in cellular neuroscience, 2019. 13: p. 162.
44. Shiradkar, M.R., et al., *A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease.* Bioorganic & medicinal chemistry, 2007. 15(19): p. 6397-6406.
45. Siddiqui, N., et al., *International Journal of Drug Development & Research| October-December 2011| Vol. 3| Issue 4| ISSN 0975-9344| Available online http://www. ijddr. in Covered in Official Product of Elsevier, The Netherlands© 2010 IJDDR.* Int. J. Drug Dev. & Res, 2011. 3(4): p. 156-164.
46. Khatik, G.L., et al., *A retrospect study on thiazole derivatives as the potential antidiabetic agents in drug discovery and developments.* Current drug discovery technologies, 2018. 15(3): p. 163-177.
47. Chen, K., et al., *Thiazole-based and thiazolidine-based protein tyrosine phosphatase 1B inhibitors as potential anti-diabetes agents.* Medicinal Chemistry Research, 2021. 30(3): p. 519-534.
48. Xu, Q., et al., *Design, synthesis and biological evaluation of thiazole-and indole-based derivatives for the treatment of type II diabetes.* European journal of medicinal chemistry, 2012. 52: p. 70-81.
49. Iida, T., et al., *Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.* European Journal of Medicinal Chemistry, 2018. 158: p. 832-852.
50. Kitas, E., et al., *Sulfonylureido thiazoles as fructose-1, 6-bisphosphatase inhibitors for the treatment of Type-2 diabetes.* Bioorganic & medicinal chemistry letters, 2010. 20(2): p. 594-599.
51. King, A.J., *The use of animal models in diabetes research.* British journal of pharmacology, 2012. 166(3): p. 877-894.
52. King, A. and J. Bowe, *Animal models for diabetes: understanding the pathogenesis and finding new treatments.* Biochemical pharmacology, 2016. 99: p. 1-10.
53. Mayer, G. and P.V. Taberner, *Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse.* European Journal of Pharmacology, 2002. 454(1): p. 95-102.
54. Lin, M.H., et al., *Identification of morin as an agonist of imidazoline I-3 receptor for insulin secretion in diabetic rats.* Naunyn-Schmiedeberg's Archives of Pharmacology, 2017. 390(10): p. 997-1003.
55. Wang, C.-Z., et al., *5-amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channel-dependent and-independent pathways.* Biochemical and biophysical research communications, 2005. 330(4): p. 1073-1079.
56. Szkudelski, T. and K. Szkudelska, *The relevance of AMP-activated protein kinase in insulin-secreting β*

cells: a potential target for improving β cell function? Journal of physiology and biochemistry, 2019. 75(4): p. 423-432.
57. Narasimhan, B., D. Sharma, and P. Kumar, *Biological importance of imidazole nucleus in the new millennium.* Medicinal Chemistry Research, 2011. 20(8): p. 1119-1140.
58. Nyblom, H.K., E. Sargsyan, and P. Bergsten, *AMP-activated protein kinase agonist dose dependently improves function and reduces apoptosis in glucotoxic b-cells without changing triglyceride levels.* Journal of Molecular Endocrinology, 2008. 41: p. 187-194.
59. McKiney, J.M., et al., *Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells.* 2010.
60. Langelueddecke, C., et al., *Effect of the AMP-kinase modulators AICAR, metformin and compound C on insulin secretion of INS-1E rat insulinoma cells under standard cell culture conditions.* Cellular Physiology and Biochemistry, 2012. 29(1-2): p. 75-86.
61. Rutter, G.A., et al., *Pancreatic β-cell identity, glucose sensing and the control of insulin secretion.* Biochemical Journal, 2015. 466(2): p. 203-218.
62. Crane, L., et al., *Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.* Bioorganic & medicinal chemistry, 2006. 14(22): p. 7419-7433.
63. Han, M.S. and D.H. Kim, *Effect of zinc ion on the inhibition of carboxypeptidase A by imidazole-bearing substrate analogues.* Bioorganic & medicinal chemistry letters, 2001. 11(11): p. 1425-1427.
64. Minoura, H., et al., *Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.* European journal of pharmacology, 2004. 494(2-3): p. 273-281.
65. Sime, M., et al., *Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist.* Bioorganic & medicinal chemistry letters, 2011. 21(18): p. 5568-5572.
66. Goebel, M., et al., *Characterization of new PPARγ agonists: benzimidazole derivatives–the importance of position 2.* ChemMedChem: Chemistry Enabling Drug Discovery, 2009. 4(7): p. 1136-1142.
67. Casimiro-Garcia, A., et al., *Discovery of a series of imidazo [4, 5-b] pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.* Journal of medicinal chemistry, 2011. 54(12): p. 4219-4233.
68. Kouskoumvekaki, I., et al., *Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.* Journal of chemical information and modeling, 2013. 53(4): p. 923-937.
69. Kurukulasuriya, R., et al., *Prospects for pharmacologic inhibition of hepatic glucose production.* Current medicinal chemistry, 2003. 10(2): p. 99-121.
70. Goyard, D., et al., *Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.* Organic & Biomolecular Chemistry, 2020. 18(5): p. 931-940.
71. Liang, Y., et al., *Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.* Diabetes, 2004. 53(2): p. 410-417.
72. Sloop, K.W., et al., *Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.* The Journal of clinical investigation, 2004. 113(11): p. 1571-1581.
73. Biftu, T., et al., *(3R)-4-[(3R)-3-Amino-4-(2, 4, 5-trifluorophenyl) butanoyl]-3-(2, 2, 2-trifluoroethyl)-1, 4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.* Bioorganic & medicinal chemistry letters, 2007. 17(1): p. 49-52.
74. Kim, R.M., et al., *Discovery of potent, orally active benzimidazole glucagon receptor antagonists.* Bioorganic & medicinal chemistry letters, 2008. 18(13): p. 3701-3705.
75. Printz, R.L., M.A. Magnuson, and D.K. Granner, *Mammalian glucokinase.* Annual review of nutrition, 1993. 13(1): p. 463-496.
76. Petersen, K. and J. Sullivan, *Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans.* Diabetologia, 2001. 44(11): p. 2018-2024.
77. Wallace, M.B., et al., *Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.* Bioorganic & medicinal chemistry letters, 2008. 18(7): p. 2362-2367.
78. Matschinsky, F.M., *A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm.* Diabetes, 1996. 45(2): p. 223-241.
79. Matschinsky, F.M., B. Glaser, and M.A. Magnuson, *Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities.* Diabetes, 1998. 47(3): p. 307-315.
80. Sarabu, R. and J. Grimsby, *Targeting glucokinase activation for the treatment of type 2 diabetes--a status review.* Current opinion in drug discovery & development, 2005. 8(5): p. 631-637.
81. Castelhano, A.L., et al., *Glucokinase-activating ureas.* Bioorganic & Medicinal chemistry letters, 2005. 15(5): p. 1501-1504.

82. McKerrecher, D., et al., *Discovery, synthesis and biological evaluation of novel glucokinase activators.* Bioorganic & medicinal chemistry letters, 2005. 15(8): p. 2103-2106.
83. Kumar, J.A., et al., *New antihyperglycemic, α-glucosidase inhibitory, and cytotoxic derivatives of benzimidazoles.* Journal of enzyme inhibition and medicinal chemistry, 2010. 25(1): p. 80-86.
84. Drucker, D.J. and M.A. Nauck, *The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.* The Lancet, 2006. 368(9548): p. 1696-1705.
85. Herman, G.A., et al., *Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.* The Journal of Clinical Pharmacology, 2006. 46(8): p. 876-886.
86. Ahrén, B., et al., *Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.* Diabetes care, 2004. 27(12): p. 2874-2880.
87. Miyamoto, Y., et al., *Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.* Bioorganic & medicinal chemistry, 2011. 19(1): p. 172-185.
88. Lam, B., et al., *Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.* Bioorganic & medicinal chemistry letters, 2012. 22(21): p. 6628-6631.
89. Kondo, T., et al., *Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.* Bioorganic & medicinal chemistry, 2008. 16(4): p. 1613-1631.
90. Rathi, A.K., et al., *Piperazine derivatives for therapeutic use: a patent review (2010-present).* Expert opinion on therapeutic patents, 2016. 26(7): p. 777-797.
91. Lan, H., et al., *GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.* Journal of Endocrinology, 2009. 201(2): p. 219.
92. Blad, C.C., C. Tang, and S. Offermanns, *G protein-coupled receptors for energy metabolites as new therapeutic targets.* Nature reviews Drug discovery, 2012. 11(8): p. 603-619.
93. Boyle, C.D., et al., *Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders*. 2013, Google Patents.
94. Pilkis, S.J. and D. Granner, *Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis.* Annual review of physiology, 1992. 54(1): p. 885-909.
95. Gerich, J.E., et al., *Renal gluconeogenesis: its importance in human glucose homeostasis.* Diabetes care, 2001. 24(2): p. 382-391.
96. Shah, A.M. and F.E. Wondisford, *Tracking the carbons supplying gluconeogenesis.* Journal of Biological Chemistry, 2020. 295(42): p. 14419-14429.
97. Ramesh, B. and K. Pugalendi, *Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats.* Journal of medicinal food, 2006. 9(4): p. 562-566.
98. Ji, H., et al., *Synthesis and anticancer activity of new coumarin-3-carboxylic acid derivatives as potential lactate transport inhibitors.* Bioorganic & Medicinal Chemistry, 2021. 29: p. 115870.
99. Zhang, X., et al., *Unraveling the regulation of hepatic gluconeogenesis. Front Endocrinol. 2019; 9*. 2018.
100. Ranđelović, S. and R. Bipat, *A Review of Coumarins and Coumarin-Related Compounds for Their Potential Antidiabetic Effect.* Clinical Medicine Insights: Endocrinology and Diabetes, 2021. 14: p. 11795514211042023.